| |
|
|
|
|
|
 |
| |
|
¾ËŰí ALTEGO[Alkyl diaminoethyl glycine hydrochloride , Ethanol]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A17200971]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2008.03.01)(ÇöÀç¾à°¡)
\0 ¿ø/1ml(2001.08.08)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ƯÀÌÇÑ ³¿»õ°¡ ³ª´Â ¾×Á¦¸¦ ÀüÁú±ÕµîÇÏ°Ô ÈíÂø½ÃŲ ¹é»öÀÇ Å»Áö¸é [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
50ml,1L,10L,18L
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¼Õ, ÇǺμҵ¶, ¼ö¼úºÎÀ§ÀÇ ÇǺμҵ¶, ¼ö¼úºÎÀ§ÀÇ Á¡¸·¼Òµ¶, ÇǺÎÁ¡¸·ÀÇ ¼Òµ¶, â»óºÎÀ§ÀÇ ¼Òµ¶.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:407800CLQ ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¼Òµ¶ ºÎÀ§¸¦ µµÆ÷ÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
µå¹°°Ô ¹ßÁø, °¡·Á¿òÁõ µîÀÇ °ú¹ÎÁõ»óÀÌ ¾ÒÀ¸¸ç, ÇǺÎÀÚ±ØÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: ETHANOLETHAMOLIN (ETHANOLAMINE OLEATE)
PREZISTA (DARUNAVIR ETHANOLATE)
±âÁØ ¼ººÐ: ALKYL DIAMINOETHYL GLYCINE HYDROCHLORIDE
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ethanol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
glycine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS.
Ethanol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes.
|
| Pharmacology |
glycine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.
Ethanol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations.
|
| Metabolism |
Ethanol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2E1 (CYP2E1)
|
| Half-life |
Ethanol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
glycine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine via an active transport mechanism.
Ethanol¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed.
|
| Pharmacokinetics |
EthanolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ¾à 20%´Â À§¿¡¼, 80%´Â ¼ÒÀå¿¡¼ Èí¼öµÈ´Ù. Áõ±â »óÅ·δ Æó·Îµµ Èí¼öµÉ ¼ö ÀÖ´Ù.
- ºÐÆ÷ :
- ŹÝÀ» ½Å¼ÓÇϰÔ, Àß Åë°úÇϸç, À¯ÁóÀ¸·Îµµ ½Å¼ÓÇÏ°Ô ºÐºñµÈ´Ù.
- ü³» ¸ðµç Á¶Á÷°ú ü¾×¿¡ °ñ°í·ç ±ÕµîÇÏ°Ô ºÐÆ÷ÇÑ´Ù.
- ºÐÆ÷¿ëÀû : 0.53 L/kg (¸¸¼º ¼·Ãë½Ã ³²¼º¿¡¼´Â Áõ°¡ÇÔ)
- ´ë»ç :
- 90-98%´Â °£¿¡¼ alcohol dehydrogenase, aldehyde dehydrogenase¿¡ ÀÇÇØ acetaldehyde, acetyl-CoA·Î Â÷·Ê´ë·Î ´ë»çµÈ ÈÄ citric acid cycleÀ» ÅëÇØ »êȵȴÙ. ƯÈ÷ ÀÌ °æ·ÎÀÇ ´ë»ç°úÁ¤Àº 0Â÷ ¹ÝÀÀ¼Óµµ¸¦ µû¸¥´Ù.
- ÀϺδ °£ÀÇ sER (smooth endoplasmic reticulum)ÀÇ cytochrome P-450 È¿¼Ò°è¿¡ ÀÇÇØ »êȵȴÙ.
- ¹Ý°¨±â : ¿ë·®ÀÇÁ¸Àû
- ¼Ò½Ç : ÁÖ·Î ½Å¹è¼³ (2-10%´Â ¹Ìº¯Èü·Î ½Å¹è¼³)µÇ¸ç, ÀϺδ Æó¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
|
| Biotransformation |
glycine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
Ethanol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1.
|
| Toxicity |
glycine¿¡ ´ëÇÑ Toxicity Á¤º¸ ORL-RAT LD50 7930 mg/kg, SCU-RAT LD50 5200 mg/kg, IVN-RAT LD50 2600 mg/kg, ORL-MUS LD50 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole.
Ethanol¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage.
|
| Drug Interactions |
glycine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Ethanol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Ethanol¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
|
| Drug Target |
[Drug Target]
|
| Description |
glycine¿¡ ´ëÇÑ Description Á¤º¸ A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem]
Ethanol¿¡ ´ëÇÑ Description Á¤º¸ A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [PubChem]
|
| Dosage Form |
glycine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IrrigationSolution Intraperitoneal
Ethanol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol TopicalGel TopicalLiquid IntramuscularLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalSolution TopicalSolution / drops OralSpray Topical
|
| Drug Category |
glycine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementGlycine AgentsMicronutrientNon-Essential Amino Acids
Ethanol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, LocalCentral Nervous System DepressantsDisinfectantsSolvents
|
| Smiles String Canonical |
glycine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCC(O)=O
Ethanol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCO
|
| Smiles String Isomeric |
glycine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCC(O)=O
Ethanol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCO
|
| InChI Identifier |
glycine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H
Ethanol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
|
| Chemical IUPAC Name |
glycine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-aminoacetic acid
Ethanol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ ethanol
|
| Drug-Induced Toxicity Related Proteins |
ETHANOL ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Proenkephalin Drug:ethanol Toxicity:ethanol narcosis. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 1 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Phosphatidylinositol-4-phosphate 3-kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 2 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase(Erk2) Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-09-27
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|